NDLI: Cyclin D1 expression in non-small-cell lung cancers: its association with altered p53 expression, cell proliferation and clinical outcome

Content Provider	PubMed Central
Author	Mishina, T. Dosaka-akita, H. Hommura, F. Morikawa, T. Katoh, H. Kawakami, Y. Kinoshita, I.
Copyright Year	1999
Abstract	Cyclin D1, like p16INK4 (p16) and retinoblastoma (RB) proteins, participates in the cell cycle control at the G1–S transition. We have previously demonstrated altered p16 and RB protein status in non-small-cell lung cancers (NSCLCs) and their potential synergistic effect with altered p53 protein on proliferative activity (Kinoshita et al (1996) Cancer Res 56: 5557–5562). In the present study, cyclin D1 expression was studied by immunohistochemistry in the same cohort of 111 resected NSCLCs as in our previous study, and the amount of the cyclin D1 gene was analysed by Southern blot analysis in 29 NSCLCs. Cyclin D1 expression was analysed in relation to the status of p53, p16 and RB proteins, and proliferative activity determined by the Ki-67 index. It was also analysed in relation to survival of 77 patients with NSCLCs which were potentially curatively resected between 1990 and 1995. We found that: (1) cyclin D1 was expressed in 13 (11.7%) of 111 NSCLCs; (2) the cyclin D1 gene was neither significantly amplified nor rearranged; (3) cyclin D1 expression significantly correlated with altered p53 protein expression (P = 0.04), whereas it did not correlate with p16 and RB protein status; (4) proliferative activity tended to be higher in cyclin D1-positive (+) tumours than in cyclin D1-negative (–) tumours, although this difference was not statistically significant (P = 0.08); and (5) patients with cyclin D1+ tumours survived longer than patients with cyclin D1– tumours (5-year survival rates, 89% and 64% respectively, by the Kaplan–Meier method; P = 0.045 by the log-rank test), and cyclin D1 expression tended to be a favourable prognostic factor (P = 0.08 in univariate analysis). These findings suggest the involvement of cyclin D1 in the development and progression of NSCLCs, their proliferative activity and clinical outcome of NSCLC patients. © 1999 Cancer Research Campaign
Related Links	http://dx.doi.org/10.1038/sj.bjc.6990500
Ending Page	1295
Page Count	7
Starting Page	1289
File Format	PDF
ISSN	15321827
e-ISSN	15321827
Journal	British Journal of Cancer
Issue Number	8
Volume Number	80
Language	English
Publisher	Nature Publishing Group
Publisher Date	1999-04-01
Access Restriction	Open
Rights Holder	Nature Publishing Group
Subject Keyword	Cancer Research Oncology Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Cancer Research Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Cyclin D1 expression in non-small-cell lung cancers: its association with altered p53 expression, cell proliferation and clinical outcome

Galectin-3 and cyclin D1 expression in non-small cell lung cancer

Galectin-3 and cyclin D1 expression in non-small cell lung cancer

Expression of c-kit and p53 in Non-small Cell Lung Cancers

DRAM2 acts as an oncogene in non-small cell lung cancer and suppresses the expression of p53

The depletion of PinX1 involved in the tumorigenesis of non-small cell lung cancer promotes cell proliferation via p15/cyclin D1 pathway

Expression of Cyclin D1 and Its Association with Disease Characteristics in Bladder Cancer

The Prognostic Value of Altered eIF3a and Its Association with p27 in Non-Small Cell Lung Cancers

Cyclin D1 expression is correlated with cell differentiation and cell proliferation in oral squamous cell carcinomas

Cyclin D1 expression in non-small-cell lung cancers: its association with altered p53 expression, cell proliferation and clinical outcome

Similar Documents

Cyclin D1 expression in non-small-cell lung cancers: its association with altered p53 expression, cell proliferation and clinical outcome

Galectin-3 and cyclin D1 expression in non-small cell lung cancer

Galectin-3 and cyclin D1 expression in non-small cell lung cancer

Expression of c-kit and p53 in Non-small Cell Lung Cancers

DRAM2 acts as an oncogene in non-small cell lung cancer and suppresses the expression of p53

The depletion of PinX1 involved in the tumorigenesis of non-small cell lung cancer promotes cell proliferation via p15/cyclin D1 pathway

Expression of Cyclin D1 and Its Association with Disease Characteristics in Bladder Cancer

The Prognostic Value of Altered eIF3a and Its Association with p27 in Non-Small Cell Lung Cancers

Cyclin D1 expression is correlated with cell differentiation and cell proliferation in oral squamous cell carcinomas

Cyclin D1 expression in non-small-cell lung cancers: its association with altered p53 expression, cell proliferation and clinical outcome